The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19.

ABSTRACT:

Background

COVID-19 clinical course is highly variable and secondary infections contribute to COVID-19 complexity. Early detection of secondary infections is clinically relevant for patient outcome. Procalcitonin (PCT) and C-reactive protein (CRP) are the most used biomarkers of infections. Pentraxin 3 (PTX3) is an acute phase protein with promising performance as early biomarker in infections. In patients with COVID-19, PTX3 plasma concentrations at hospital admission are independent predictor of poor outcome. In this study, we assessed whether PTX3 contributes to early identification of co-infections during the course of COVID-19.

Methods

We analyzed PTX3 levels in patients affected by COVID-19 with (n = 101) or without (n = 179) community or hospital-acquired fungal or ba

SUBMITTER: Scavello F 

PROVIDER: S-EPMC11245991 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature